Company Interview / Cyclopharm eyeing profitability amid US expansion

James McBrayer, Cyclopharm CEO, (ASX: CYC) discusses the company's record performance, revealing $27.6M in revenue, mainly driven by 'Technegas' sales. With its US expansion underway, the company has achieved significant progress despite encountering delays in the approval process.

James outlines Cyclopharm’s (ASX: CYC) strategic partnerships and contracts, including those with HCA and the Department of Defense. He emphasises the conservative outlook due to uncertainties in US healthcare and politics yet remains optimistic about installations and growth prospects.

Focusing on broadening the application of their diagnostic products, particularly for pulmonary embolism, Cyclopharm plans to invest in R&D and leverage a strong global footprint and the weaker Aussie dollar for US market advantage. James remains focused on execution amid investor scrutiny.